ArticlePLoS neglected tropical diseases2026
Host immune network-guided reverse vaccinology approach for prioritizing candidate antigens in Schistosoma japonicum-associated liver fibrosis.
Article in PLoS neglected tropical diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Schistosoma japonicum-associated liver fibrosis (SSLF) remains a major cause of long-term morbidity in schistosomiasis, even in post-control or low-transmission settings. While most vaccine development efforts have focused on reducing parasite burden, few approaches have incorporated host pathology related to liver fibrosis. This study developed an in silico strategy that combined host single-cell analysis with reverse vaccinology to guide the exploratory screening of parasite antigens with potential relevance to SSLF. Single-cell transcriptomics of fibrotic and control human liver tissues was used to identify immune-related molecular networks and host proteins associated with fibrosis-related pathology in the available dataset. In parallel, antigens were screened by functional annotation and established reverse-vaccinology criteria. Candidate antigens were further assessed by docking against selected host proteins. Docking of a known FYN inhibitor was included as a structural reference to interpret the strongest predicted antigen-host interaction. Single-cell analyses identified FYN, BCL2, and AKT3 as key nodes in fibrosis-associated immune networks. Among screened parasite antigens, DRE2_SCHJA, an Anamorsin homolog involved in iron-sulfur cluster assembly, emerged as a computational candidate for further validation. Docking predicted that DRE2_SCHJA may bind in an SH2-associated region of FYN, whereas the Saracatinib-FYN model was centered on the ATP-binding pocket of the kinase domain. This difference may suggest a distinct predicted binding mode rather than Saracatinib-like kinase inhibition. Overall, the vaccine-screening profile and predicted FYN-associated interaction may provide a computational rationale for further experimental evaluation of DRE2_SCHJA as a candidate antigen in the immune-fibrotic context of SSLF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.